Search

Displaying results 1371 - 1380 of 6835 in total
  1. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    [T683] Metoclopramide was initially approved by the FDA in 1980.[A184922] … [A184934] Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
  2. Drug

    Diethylamino hydroxybenzoyl hexyl benzoate

    go.drugbank.com/drugs/DB11269
    Approved

    Minimizing the overexposure of human skin to ultraviolet radiation that may lead to acute and chronic photodamage, diethylamino hydroxybenzoyl hexyl benzoate is an oil-soluble UV filter that may be incorporated … It has a chemical structure similar to the classical benxophoenone drug class, and displays good photostability [A33171].

    Mixtures: D-one By Tamdoan Bb Light, D-one By Tamdoan Bb Medium
  3. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.

  4. Drug

    Enalapril

    go.drugbank.com/drugs/DB00584
    ApprovedInvestigationalVet approved

    Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume. … Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction.

    Mixtures: CO-RENITEC, Co-Mepril - Tabletten
  5. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.

  6. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]

  7. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.

  8. Drug

    Hydroxyethyl Starch

    go.drugbank.com/drugs/DB09106
    ApprovedInvestigational

    Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. … HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.

  9. Target

    Zinc finger and BTB domain-containing protein 7A

    go.drugbank.com/bio_entities/BE0012406
    TargetHumans

    Also directly interacts with transcription factors like SP1 to prevent their binding to DNA (PubMed:12004059). … Collaborates with transcription factors like RELA to modify the accessibility of gene transcription regulatory regions to secondary transcription factors (By similarity).

    Synonyms: Factor that binds to inducer of short transcripts protein 1
  10. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.